Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target

Benzinga · 2d ago
Guggenheim analyst Michael Schmidt reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $28 price target.